[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease

Publisher Website
Google Scholar
Abstract
The aim of this study was to compare two PET ligands, 6-[18F]fluoro-L-dopa ([18F]FDOPA) and 18F-labeled CFT, 2β-carbomethoxy-3β-(4-[18F]-fluorophenyl)tropane ([18F]CFT), in detecting presynaptic dopaminergic hypofunction in early Parkinson's disease (PD). These ligands reflect different aspects of presynaptic dopaminergic function, since [18F]FDOPA mainly reflects 6-[18F]fluorodopamine (fluorodopamine) synthesis and storage whereas [18F]CFT uptake is related to dopamine transporter function. Eight de novo patients with PD who had never been on antiparkinsonian medication were investigated with [18F]FDOPA and [18F]CFT PET. Five healthy volunteers were studied as controls. In PD patients, both [18F]FDOPA and [18F]CFT uptakes were significantly reduced both in the contralateral and ipsilateral anterior and posterior putamen. The reduction was greatest in the contralateral posterior putamen (to 28% of control mean for [18F]FDOPA, P < 0.0001 and to 16% for [18F]CFT, P < 0.0001). Individually, all patients' [18F]FDOPA and [18F]CFT uptake values in the contralateral anterior and posterior putamen were below 3 SD of the control mean. In the caudate nucleus, the mean uptake of both tracers was significantly reduced both ipsilaterally and contralaterally, but less severely than in the putamen (to 69% of the control mean for [18F]FDOPA, P = 0.003 and to 60% for [18F]CFT, P = 0.001 contralaterally). Our results show that both [18F]FDOPA as well as [18F]CFT sensitively detect presynaptic dopaminergic hypofunction in early PD. They demonstrate a considerable reduction of tracer uptake that is greatest in the posterior putamen, followed by the anterior putamen and the caudate nucleus. Synapse 40:193–200, 2001.

This publication has 41 references indexed in Scilit: